Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Recruiting
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD. Participants will be asked to:... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/10/2025
Locations: University of New Mexico Health Sciences Center, Albuquerque, New Mexico
Conditions: MASLD, Obesity